VivoSim forecasts FY2027 revenue growth of 500%+

VivoSim Labs Inc

VivoSim Labs Inc

VIVS

0.00
  • VivoSim forecast FY2027 revenue growth of more than 500%, citing rising demand for its NAM-based contract research services from drugmakers.
  • Guidance followed receipt of a USD 5 million Eli Lilly milestone tied to first patient dosing in a Phase 2 study of a former VivoSim IBD drug.
  • Eligible for up to USD 45 million in additional Lilly milestones if the program meets future regulatory and commercial targets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150805PRIMZONEFULLFEED9762551) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.